Kailos Genetics
Huntsville, US · Founded 2010 · Delaware corporation · 1 known investors
Kailos Genetics provides precision medicine solutions using its TargetRich enrichment technology, next-generation sequencing, and analytics, offering customizable sequencing panels and sample processing through its CAP-accredited, CLIA-certified clinical laboratory. It serves research and clinical laboratories, and offers reduced-cost hereditary cancer risk testing to North Alabama residents.
Founders & leadership
RC
Randall C. BachmeyerExecutive
BK
Brian K. PollockExecutive
CL
Cheri L. WalkerExecutive
DT
David Troy MooreNamed on SEC filing
MJ
Michael J WaltersNamed on SEC filing
RC
Randall C BachmeyerNamed on SEC filing
KT
Katherine T VarleyNamed on SEC filing
BP
Brian PollockNamed on SEC filing
Board
JR
James R. Hudson, Jr.Board director
KT
Katherine T. VarleyBoard director
DW
Danny WindhamBoard director
MJ
Michael J. WaltersBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$2M disclosed across 1 of 4 rounds · 2014–2018
▶$2MraisedApr 2018 · 8 investors · BiotechnologyRule 506(b)
▶$2MraisedApr 2018 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael J. WaltersDirector
- Danny WindhamDirector
- David Troy MooreExecutive Officer, Director
- Brian K. PollockExecutive Officer, Director
- Randall C. BachmeyerExecutive Officer
- Cheri WalkerExecutive Officer
- James R. Hudson, Jr.Director
- Katherine T. VarleyDirector
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MofferedNov 2016 · BiotechnologyRule 506(b)
▶$2MofferedNov 2016 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Michael J. WaltersDirector
- Katherine T. VarleyDirector
- Randall C. BachmeyerExecutive Officer
- David Troy MooreExecutive Officer, Director
- Brian K. PollockExecutive Officer, Director
- Offering amount
- $2M
- Minimum investment
- $25K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4MofferedAug 2015 · BiotechnologyRule 506(b)
▶$4MofferedAug 2015 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Katherine T. VarleyDirector
- Randall C. BachmeyerExecutive Officer
- Brian K. PollockExecutive Officer, Director
- James R. Hudson, Jr.Director
- Danny WindhamDirector
- David Troy MooreExecutive Officer, Director
- Michael J. WaltersDirector
- Cheri L. WalkerExecutive Officer
- Offering amount
- $4M
- Minimum investment
- $100K
- Proceeds to insiders
- $180K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MofferedJul 2014 · BiotechnologyRule 506(b)
▶$2.5MofferedJul 2014 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David Troy MooreExecutive Officer, Director
- Michael J WaltersExecutive Officer, Director
- Randall C BachmeyerExecutive Officer
- James R. Hudson, Jr.Director
- Danny WindhamDirector
- Katherine T VarleyDirector
- Brian PollockExecutive Officer, Director
- Offering amount
- $2.5M
- Minimum investment
- $100K
- Incorporated
- Corporation, Delaware, 2010
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapAmerican Cancer Society (ACS)155 shared keywordsThe American Cancer Society is a nonprofit cancer-fighting organization that combats cancer through advocacy, research, and patient support. It provides information, guidance, caregiver resources, screening guidance, and clinical trial navigation for cancer patients, families, and caregivers, and funds cancer research.
MD Anderson Cancer Center114 shared keywordsUT MD Anderson is a cancer hospital providing cancer treatment, prevention, clinical care, and research, including new therapies and clinical trials for cancer patients. It is ranked among the top hospitals in the U.S. for cancer care.
Cancerresearchuk111 shared keywordsCancer Research UK funds research across discovery, detection, prevention and treatment of cancer to improve patient outcomes and extend survival. It operates as a research funder and scientific organization serving academic and clinical researchers.
Companies competing with Kailos Genetics for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Kailos Genetics do?
- Kailos Genetics provides precision medicine solutions using its TargetRich enrichment technology, next-generation sequencing, and analytics, offering customizable sequencing panels and sample processing through its CAP-accredited, CLIA-certified clinical laboratory. It serves research and clinical laboratories, and offers reduced-cost hereditary cancer risk testing to North Alabama residents.
- Who are Kailos Genetics's investors?
- Kailos Genetics's investors include New Capital Partners.
- How much funding has Kailos Genetics raised?
- Kailos Genetics has disclosed $2M raised across 1 of its 4 known rounds.
- Where is Kailos Genetics headquartered?
- Kailos Genetics is headquartered in Huntsville, US.